Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response

Rau, Kung-Ming; Liu, Chien-Ting; Hsiao, Yu-Chiao; Hsiao, Kai-Yin; Wang, Tzu-Min; Hung, Wei-Shan; Su, Yu‐Li; Liu, Wei-Ching; Wang, Cheng‐Hsu; Hsu, Hsueh-Ling; Chuang, Po‐Heng; Cheng, Ju‐Chien; Tseng, Ching‐Ping

doi:10.3390/jcm9010188

Cited by 15 publications

(10 citation statements)

References 44 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no significant correlation was identified between changes in CTC levels and all the radiofrequency ablation factors. Recently, Rau et al [104] demonstrated the clinical utilities of sequential CTC monitoring in a patient cohort (n = 17) with locally advanced or metastatic HCC accepted systemic/targeted therapy. They found that a change in the CTC count correlated with the patient treatment response in most of the cases and was particularly useful for monitoring patients without elevated serum AFP levels.…”

Section: Tumor Monitoring and Guiding Personalized Therapeutic Intervmentioning

confidence: 99%

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Wang¹,

Yang²

2020

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide and is associated with poor clinical prognosis, which is mainly caused by tumor recurrence and metastasis. Circulating tumor cells (CTCs) are tumor cells shed into the bloodstream and regarded as the "seeds" of tumor recurrent or metastatic lesions. Over the past decade, the clinical value of CTC analysis has been extensively explored. CTC analysis is a representative form of liquid biopsy, offering a novel solution that can bypass the problems of invasive biopsy procedures, enabling comprehensive, non-invasive, and real-time disease monitoring. In HCC, CTC analysis has facilitated early detection and prognosis prediction, as well as treatment monitoring and therapeutic intervention guiding. In this review, we summarize available literature and provide an overview of CTC biology, detection technologies, and clinical applications in the diagnosis, prognosis prediction, and personalized treatment of HCC.

show abstract

Section: Tumor Monitoring and Guiding Personalized Therapeutic Intervmentioning

confidence: 99%

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Wang¹,

Yang²

2020

View full text Add to dashboard Cite

show abstract

“…It was expected that with chemotherapy treatment, there would be a decrease in CTCs and thus a decrease in HIF-1α, GLUT1 and CAIX expression. However, some studies have shown that even under different chemotherapy treatments, the number of CTCs varies considerably, increasing and decreasing throughout treatment 39 . This oscillation may be the reason that we have not detected alterations in gene expression throughout its treatment.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic potential of hypoxia-induced genes in liquid biopsies of breast cancer patients

Peiró

Perez

Aquino

et al. 2021

Sci Rep

View full text Add to dashboard Cite

In tumor cells, higher expression of glucose transporter proteins (GLUT) and carbonic anhydrases (CAIX) genes is influenced by hypoxia-induced factors (HIF).Thus, we aimed to study the expression profile of these markers in sequential peripheral blood collections performed in breast cancer patients in order to verify their predictive potential in liquid biopsies. Gene expressions were analyzed by qPCR in tumor and blood samples from 125 patients and 25 healthy women. Differential expression was determined by the 2(−ΔCq) method. Expression of HIF-1α and GLUT1 in the blood of breast cancer patients is significantly higher (90–91 and 160–161 fold increased expression, respectively; p < 0.0001) than that found in healthy women. Their diagnostic power was confirmed by ROC curve. CAIX is also more expressed in breast cancer women blood, but its expression was detected only in a few samples. But none of these genes could be considered predictive markers. Therefore, evaluation of the expression of HIF-1α and GLUT1 in blood may be a useful laboratory tool to complement the diagnosis of breast cancer, in addition to being useful for follow-up of patients and of women with a family history of breast cancer.

show abstract

“…Rau et al investigated the CTC count in HCC patients during longitudinal follow-up before and at different time points during systemic/targeted therapy. They showed that changes in the CTC count correlate with the patients' treatment response in most cases and were particularly useful for monitoring HCC with low AFP levels (<100 ng/ml) (80). In patients with AFP<100 ng/ml who were originally treated with sorafenib alone, or who were afterwards enrolled in clinical trials with systemic therapy by ramucirumab and intravenous chemotherapy (IV-CT) or intra-arterial chemotherapy (IA-CT), CTC counts decreased and were consistent with the disease status.…”

Section: Phenotyping and Genotyping Of Circulating Tumor Cellsmentioning

confidence: 99%

Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine

Moldogazieva

Zavadskiy

Terentiev

2021

Cancer Genomics Proteomics

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the sixth most frequently diagnosed cancer and the third leading cause of cancer-related deaths worldwide. Advanced-stage HCC patients have poor survival rates and this requires the discovery of novel clear biomarkers for HCC early diagnosis and prognosis, identifying risk factors, distinguishing HCC from non-HCC liver diseases, and assessment of treatment response. Liquid biopsy has emerged as a novel minimally invasive approach to enable monitoring tumor progression, metastasis, and recurrence. Since the liquid biopsy analysis has relatively high specificity and low sensitivity in cancer early detection, there is a risk of bias. Next-generation sequencing (NGS) technologies provide accurate and comprehensive gene expression and mutational profiling of liquid biopsies including cell-free circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and genomic components of extracellular vesicles (EVs) including micro-RNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs). Since HCC is a highly heterogeneous cancer, HCC patients can display various genomic, epigenomic, and transcriptomic patterns and exhibit varying sensitivity to treatment options. Identification 369 This article is freely accessible online.

show abstract

Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response

Cited by 15 publications

References 44 publications

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Diagnostic potential of hypoxia-induced genes in liquid biopsies of breast cancer patients

Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine

Contact Info

Product

Resources

About